Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Survival in patients with primary pulmonary hypertension treated with intravenous epoprostenol (PGI2) according to New York Heart Association (NYHA) functional class (FC). (A) Estimated percentages of survival for patients in NYHA FC IV at baseline (dashed line) were 76%, 60%, and 47% at one, two, and three years, respectively, as compared with 90%, 76%, and 71% for patients in NYHA FC III at baseline (solid line) (p = 0.001 by the Cox-Mantel log-rank test). (B) After three months of treatment with epoprostenol, survival rates for patients reclassified in NYHA FC I or II (solid line) were 100%, 93%, and 88% at one, two, and three years, respectively, as compared with 77%, 46%, and 33% for patients persisting in NYHA FC III or IV (dashed line) (p < 0.0001 by the Cox-Mantel log-rank test).
|
